2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF II.
Finn GustafssonMark C PetrieJan KomtebeddeVijendra SwarupSebastian WinklerGerd HasenfußBarry A BorlaugRajeev C MohanJames D FlahertyAaron L SverdlovPeter S FailEugene S ChungPhilipp LurzScott LillyDavid M KayeJohn G F ClelandMaja CikesMartin B LeonDonald E CutlipDirk J van VeldhuisenScott D SolomonSanjiv J ShahPublished in: JACC. Heart failure (2024)
At 2 years of follow-up in REDUCE LAP-HF II, there was no difference in efficacy between the atrial shunt and sham groups in the overall trial group. The potential clinical benefit identified in the responder group after 1 and 2 years of follow-up is currently being evaluated in the RESPONDER-HF (Re-Evaluation of the Corvia Atrial Shunt Device in a Precision Medicine Trial to Determine Efficacy in Mildly Reduced or Preserved Ejection Fraction Heart Failure) trial. (Reduce Elevated Left Atrial Pressure in Patients With Heart Failure II [REDUCE LAP-HF II]; NCT03088033).
Keyphrases
- left atrial
- atrial fibrillation
- ejection fraction
- heart failure
- catheter ablation
- left ventricular
- acute heart failure
- phase iii
- study protocol
- mitral valve
- clinical trial
- phase ii
- pulmonary artery
- aortic stenosis
- randomized controlled trial
- adipose tissue
- coronary artery
- pulmonary hypertension
- risk assessment
- metabolic syndrome
- skeletal muscle
- cardiac resynchronization therapy
- pulmonary arterial hypertension